-
2
-
-
0025869216
-
Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease
-
Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 1991, 324:1464-1470.
-
(1991)
N. Engl. J. Med.
, vol.324
, pp. 1464-1470
-
-
Barton, N.W.1
Brady, R.O.2
Dambrosia, J.M.3
Di Bisceglie, A.M.4
Doppelt, S.H.5
Hill, S.C.6
-
3
-
-
77954693904
-
Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience
-
Zimran A., Altarescu G., Philips M., Attias D., Jmoudiak M., Deeb M., Wang N., Bhirangi K., Cohn G.M., Elstein D. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 2010, 115(23):4651-4656.
-
(2010)
Blood
, vol.115
, Issue.23
, pp. 4651-4656
-
-
Zimran, A.1
Altarescu, G.2
Philips, M.3
Attias, D.4
Jmoudiak, M.5
Deeb, M.6
Wang, N.7
Bhirangi, K.8
Cohn, G.M.9
Elstein, D.10
-
4
-
-
82155184565
-
Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease
-
Zimran A., Brill-Almon E., Chertkoff R., Petakov M., Blanco-Favela F., Muñoz E.T., Solorio-Meza S.E., Amato D., Duran G., Giona F., Heitner R., Rosenbaum H., Giraldo P., Mehta A., Park G., Phillips M., Elstein D., Altarescu G., Szleifer M., Hashmueli S., Aviezer D. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011, 118(22):5767-5773.
-
(2011)
Blood
, vol.118
, Issue.22
, pp. 5767-5773
-
-
Zimran, A.1
Brill-Almon, E.2
Chertkoff, R.3
Petakov, M.4
Blanco-Favela, F.5
Muñoz, E.T.6
Solorio-Meza, S.E.7
Amato, D.8
Duran, G.9
Giona, F.10
Heitner, R.11
Rosenbaum, H.12
Giraldo, P.13
Mehta, A.14
Park, G.15
Phillips, M.16
Elstein, D.17
Altarescu, G.18
Szleifer, M.19
Hashmueli, S.20
Aviezer, D.21
more..
-
5
-
-
0034728914
-
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
-
Cox T., Lachmann R., Hollak C., Aerts J., van W.S., Hrebicek M., et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000, 355:1481-1485.
-
(2000)
Lancet
, vol.355
, pp. 1481-1485
-
-
Cox, T.1
Lachmann, R.2
Hollak, C.3
Aerts, J.4
van, W.S.5
Hrebicek, M.6
-
6
-
-
10744226382
-
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement
-
Cox T.M., Aerts J.M., Andria G., Beck M., Belmatoug N., Bembi B., et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J. Inherit. Metab. Dis. 2003, 26:513-526.
-
(2003)
J. Inherit. Metab. Dis.
, vol.26
, pp. 513-526
-
-
Cox, T.M.1
Aerts, J.M.2
Andria, G.3
Beck, M.4
Belmatoug, N.5
Bembi, B.6
-
7
-
-
34249306894
-
A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease
-
McEachern K.A., Fung J., Komarnitsky S., Siegel C.S., Chuang W.L., Hutto E., Shayman J.A., Grabowski G.A., Aerts J.M., Cheng S.H., Copeland D.P., Marshall J. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol. Genet. Metab. 2007, 91(3):259-267.
-
(2007)
Mol. Genet. Metab.
, vol.91
, Issue.3
, pp. 259-267
-
-
McEachern, K.A.1
Fung, J.2
Komarnitsky, S.3
Siegel, C.S.4
Chuang, W.L.5
Hutto, E.6
Shayman, J.A.7
Grabowski, G.A.8
Aerts, J.M.9
Cheng, S.H.10
Copeland, D.P.11
Marshall, J.12
-
8
-
-
84908086749
-
Eliglustat, an investigationaloral therapy for Gaucher disease type 1: Phase 2 trial results after 4years of treatment
-
Lukina E., Watman N., Dragosky M., Pastores G.M., Arreguin E.A., Rosenbaum H., Zimran A., Angell J., Ross L., Puga A.C., Peterschmitt J.M. Eliglustat, an investigationaloral therapy for Gaucher disease type 1: Phase 2 trial results after 4years of treatment. Blood Cells Mol. Dis. 2014, 53(4):274-276.
-
(2014)
Blood Cells Mol. Dis.
, vol.53
, Issue.4
, pp. 274-276
-
-
Lukina, E.1
Watman, N.2
Dragosky, M.3
Pastores, G.M.4
Arreguin, E.A.5
Rosenbaum, H.6
Zimran, A.7
Angell, J.8
Ross, L.9
Puga, A.C.10
Peterschmitt, J.M.11
-
9
-
-
0028220472
-
Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease
-
Hollak C.E., van W.S., van Oers M.H., Aerts J.M. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Invest. 1994, 93:1288-1292.
-
(1994)
J. Clin. Invest.
, vol.93
, pp. 1288-1292
-
-
Hollak, C.E.1
van, W.S.2
van Oers, M.H.3
Aerts, J.M.4
-
10
-
-
9144222696
-
Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention
-
Boot R.G., Verhoek M., de F.M., Hollak C.E., Maas M., Bleijlevens B., et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 2004, 103:33-39.
-
(2004)
Blood
, vol.103
, pp. 33-39
-
-
Boot, R.G.1
Verhoek, M.2
de, F.M.3
Hollak, C.E.4
Maas, M.5
Bleijlevens, B.6
-
11
-
-
84911998784
-
Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy
-
van Dussen L., Hendriks E.J., Groener J.E., Boot R.G., Hollak C.E., Aerts J.M. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy. J. Inherit. Metab. Dis. 2014, 37(6):991-1001.
-
(2014)
J. Inherit. Metab. Dis.
, vol.37
, Issue.6
, pp. 991-1001
-
-
van Dussen, L.1
Hendriks, E.J.2
Groener, J.E.3
Boot, R.G.4
Hollak, C.E.5
Aerts, J.M.6
-
12
-
-
38649107044
-
Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease
-
Ghauharali-van der Vlugt K., Langeveld M., Poppema A., Kuiper S., Hollak C.E., Aerts J.M., Groener J.E. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin. Chim. Acta 2008, 389:109-113.
-
(2008)
Clin. Chim. Acta
, vol.389
, pp. 109-113
-
-
Ghauharali-van der Vlugt, K.1
Langeveld, M.2
Poppema, A.3
Kuiper, S.4
Hollak, C.E.5
Aerts, J.M.6
Groener, J.E.7
-
13
-
-
80054841258
-
Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response
-
Dekker N., van D.L., Hollak C.E., Overkleeft H., Scheij S., Ghauharali K., et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 2011, 118:e118-e127.
-
(2011)
Blood
, vol.118
, pp. e118-e127
-
-
Dekker, N.1
van, D.L.2
Hollak, C.E.3
Overkleeft, H.4
Scheij, S.5
Ghauharali, K.6
-
14
-
-
84894280298
-
Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients
-
Rolfs A., Giese A.K., Grittner U., Mascher D., Elstein D., Zimran A., Böttcher T., Lukas J., Hübner R., Gölnitz U., Röhle A., Dudesek A., Meyer W., Wittstock M., Mascher H. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS One 2013, 8(11):e79732.
-
(2013)
PLoS One
, vol.8
, Issue.11
, pp. e79732
-
-
Rolfs, A.1
Giese, A.K.2
Grittner, U.3
Mascher, D.4
Elstein, D.5
Zimran, A.6
Böttcher, T.7
Lukas, J.8
Hübner, R.9
Gölnitz, U.10
Röhle, A.11
Dudesek, A.12
Meyer, W.13
Wittstock, M.14
Mascher, H.15
-
15
-
-
78650614891
-
Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage
-
Mistry P.K., Liu J., Yang M., Nottoli T., McGrath J., Jain D., et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:19473-19478.
-
(2010)
Proc. Natl. Acad. Sci. U. S. A.
, vol.107
, pp. 19473-19478
-
-
Mistry, P.K.1
Liu, J.2
Yang, M.3
Nottoli, T.4
McGrath, J.5
Jain, D.6
-
16
-
-
84916227639
-
Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy
-
Pavlova E.V., Archer J.Z., Wang S., Dekker N., Aerts J.M., Karlsson S., Cox T.M. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. J. Pathol. 2015, 235(1):113-124.
-
(2015)
J. Pathol.
, vol.235
, Issue.1
, pp. 113-124
-
-
Pavlova, E.V.1
Archer, J.Z.2
Wang, S.3
Dekker, N.4
Aerts, J.M.5
Karlsson, S.6
Cox, T.M.7
-
17
-
-
84885139621
-
B cell lymphoma and myeloma in murine Gaucher's disease
-
Pavlova E.V., Wang S.Z., Archer J., Dekker N., Aerts J.M., Karlsson S., Cox T.M. B cell lymphoma and myeloma in murine Gaucher's disease. J. Pathol. 2013, 231(1):88-97.
-
(2013)
J. Pathol.
, vol.231
, Issue.1
, pp. 88-97
-
-
Pavlova, E.V.1
Wang, S.Z.2
Archer, J.3
Dekker, N.4
Aerts, J.M.5
Karlsson, S.6
Cox, T.M.7
-
18
-
-
84897550720
-
Multiplex tandem mass spectrometry analysis of novel plasmalyso-Gb[U+2083]-related analogues in Fabry disease
-
Boutin M., Auray-Blais C. Multiplex tandem mass spectrometry analysis of novel plasmalyso-Gb[U+2083]-related analogues in Fabry disease. Anal. Chem. 2014, 86(7):3476-3483.
-
(2014)
Anal. Chem.
, vol.86
, Issue.7
, pp. 3476-3483
-
-
Boutin, M.1
Auray-Blais, C.2
-
19
-
-
0022255512
-
The occurrence of two immunologically distinguishable beta-glucocerebrosidases in human spleen
-
Aerts J.M., Donker-Koopman W.E., van der Vliet M.K., Jonsson L.M., Ginns E.I., Murray G.J., Barranger J.A., Tager J.M., Schram A.W. The occurrence of two immunologically distinguishable beta-glucocerebrosidases in human spleen. Eur. J. Biochem. 1985, 150(3):565-574.
-
(1985)
Eur. J. Biochem.
, vol.150
, Issue.3
, pp. 565-574
-
-
Aerts, J.M.1
Donker-Koopman, W.E.2
van der Vliet, M.K.3
Jonsson, L.M.4
Ginns, E.I.5
Murray, G.J.6
Barranger, J.A.7
Tager, J.M.8
Schram, A.W.9
-
20
-
-
34147204029
-
HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma
-
Groener J.E., Poorthuis B.J., Kuiper S., Helmond M.T., Hollak C.E., Aerts J.M. HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma. Clin. Chem. 2007, 53:742-747.
-
(2007)
Clin. Chem.
, vol.53
, pp. 742-747
-
-
Groener, J.E.1
Poorthuis, B.J.2
Kuiper, S.3
Helmond, M.T.4
Hollak, C.E.5
Aerts, J.M.6
-
21
-
-
84874618709
-
Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry
-
Gold H., Mirzaian M., Dekker N., Joao F.M., Lugtenburg J., Codee J.D., et al. Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry. Clin. Chem. 2013, 59:547-556.
-
(2013)
Clin. Chem.
, vol.59
, pp. 547-556
-
-
Gold, H.1
Mirzaian, M.2
Dekker, N.3
Joao, F.M.4
Lugtenburg, J.5
Codee, J.D.6
-
22
-
-
33845261493
-
A rapid method of total lipid extraction and purification
-
Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37:911-917.
-
(1959)
Can. J. Biochem. Physiol.
, vol.37
, pp. 911-917
-
-
Bligh, E.G.1
Dyer, W.J.2
-
23
-
-
4344593367
-
Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages
-
Boven L.A., van M.M., Boot R.G., Mehta A., Boon L., Aerts J.M., Laman J.D. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am. J. Clin. Pathol. 2004, 122:359-369.
-
(2004)
Am. J. Clin. Pathol.
, vol.122
, pp. 359-369
-
-
Boven, L.A.1
van, M.M.2
Boot, R.G.3
Mehta, A.4
Boon, L.5
Aerts, J.M.6
Laman, J.D.7
-
24
-
-
84858712304
-
Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics
-
Mar 20
-
Auray-Blais C., Boutin M., Gagnon R., Dupont F.O., Lavoie P., Clarke J.T. Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics. Anal. Chem. Mar 20 2012, 84(6):2745-2753.
-
(2012)
Anal. Chem.
, vol.84
, Issue.6
, pp. 2745-2753
-
-
Auray-Blais, C.1
Boutin, M.2
Gagnon, R.3
Dupont, F.O.4
Lavoie, P.5
Clarke, J.T.6
-
25
-
-
84873381566
-
Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry
-
Feb 5
-
Lavoie P., Boutin M., Auray-Blais C. Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry. Anal. Chem. Feb 5 2013, 85(3):1743-1752.
-
(2013)
Anal. Chem.
, vol.85
, Issue.3
, pp. 1743-1752
-
-
Lavoie, P.1
Boutin, M.2
Auray-Blais, C.3
-
26
-
-
84877987576
-
A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers
-
Dupont F.O., Gagnon R., Boutin M., Auray-Blais C. A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers. Curr. Med. Chem. 2013, 20(2):280-288.
-
(2013)
Curr. Med. Chem.
, vol.20
, Issue.2
, pp. 280-288
-
-
Dupont, F.O.1
Gagnon, R.2
Boutin, M.3
Auray-Blais, C.4
-
28
-
-
0021813371
-
Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants
-
Nilsson O., Grabowski G.A., Ludman M.D., Desnick R.J., Svennerholm L. Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants. Clin. Genet. 1985, 27:443-450.
-
(1985)
Clin. Genet.
, vol.27
, pp. 443-450
-
-
Nilsson, O.1
Grabowski, G.A.2
Ludman, M.D.3
Desnick, R.J.4
Svennerholm, L.5
-
29
-
-
0036387220
-
Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype
-
Orvisky E., Park J.K., LaMarca M.E., Ginns E.I., Martin B.M., Tayebi N., Sidransky E. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol. Genet. Metab. 2002, 76:262-270.
-
(2002)
Mol. Genet. Metab.
, vol.76
, pp. 262-270
-
-
Orvisky, E.1
Park, J.K.2
LaMarca, M.E.3
Ginns, E.I.4
Martin, B.M.5
Tayebi, N.6
Sidransky, E.7
-
30
-
-
42949119819
-
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
-
Aerts J.M., Groener J.E., Kuiper S., Donker-Koopman W.E., Strijland A., Ottenhoff R., et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2812-2817.
-
(2008)
Proc. Natl. Acad. Sci. U. S. A.
, vol.105
, pp. 2812-2817
-
-
Aerts, J.M.1
Groener, J.E.2
Kuiper, S.3
Donker-Koopman, W.E.4
Strijland, A.5
Ottenhoff, R.6
-
31
-
-
80051817507
-
Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice
-
Durant B., Forni S., Sweetman L., Brignol N., Meng X.L., Benjamin E.R., et al. Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice. J. Lipid Res. 2011, 52:1742-1746.
-
(2011)
J. Lipid Res.
, vol.52
, pp. 1742-1746
-
-
Durant, B.1
Forni, S.2
Sweetman, L.3
Brignol, N.4
Meng, X.L.5
Benjamin, E.R.6
-
32
-
-
84925884053
-
The chemistry and biology of 6-hydroxyceramide, the youngest member of the human sphingolipid family
-
Kováčik A., Roh J., Vávrová K. The chemistry and biology of 6-hydroxyceramide, the youngest member of the human sphingolipid family. Chembiochem 2014, 15(11):1555-1562.
-
(2014)
Chembiochem
, vol.15
, Issue.11
, pp. 1555-1562
-
-
Kováčik, A.1
Roh, J.2
Vávrová, K.3
|